Literature DB >> 671246

Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans.

F R Pelsor, L M Allen, P J Creaven.   

Abstract

The formation and elimination of the metabolite of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (I) were studied in seven patients with advanced cancer who received I intravenously. The plasma concentration-time data best fit a triexponential equation. The volume of the metabolite compartment (27.5 liters) was calculated as a fraction of the extrapolated volume. A larger body clearance (111.7 ml/min) of metabolite as compared to the renal clearance (31.3 ml/min) indicates that the metabolite is lost from the plasma equivalent space by another elimination route. The combination of metabolite data presented here with previously published data for unchanged I leads to a multicompartment model for the distribution, metabolism, and excretion of I and its metabolite. A comparison of algebraically derived model transfer constants with those evaluated by computer fitting the system of differential equations is presented.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 671246     DOI: 10.1002/jps.2600670821

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

Review 3.  VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.

Authors:  J D Loike
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.

Authors:  K H Pflüger; L Schmidt; M Merkel; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

6.  Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?

Authors:  L M Allen; F Tejada; A D Okonmah; S Nordqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.

Authors:  K H Pflüger; M Hahn; J B Holz; L Schmidt; P Köhl; H W Fritsch; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.